Compare Stocks

→ “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$5.30 -2.2%	$5.91	$2.68 ▼ $8.22	$174.21M	4.06	386,679 shs	233,835 shs
ICOTF iCo Therapeutics	$0.32	$0.37	$0.80 ▼ $1.82	$2.90M	2.03	4,760 shs	1,500 shs
NVUS Novus Therapeutics	$2.31 -3.8%	$13.23	$4.50 ▼ $27.32	$3.32M	2.07	78,851 shs	193,916 shs
TRPX Therapix Biosciences	$0.10	$0.23	$0.25 ▼ $4.69	$351K	N/A	1.59 million shs	95,212 shs
XTLB XTL Biopharmaceuticals	$2.56 +6.7%	$3.99	$1.73 ▼ $6.69	$13.95M	1.24	26,245 shs	8,825 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+0.93%	+3.44%	-17.88%	+38.62%	+32.84%
ICOTF iCo Therapeutics	0.00%	0.00%	-21.95%	-21.43%	-31.91%
NVUS Novus Therapeutics	-1.64%	+4.35%	+44.58%	+42.01%	-15.79%
TRPX Therapix Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
XTLB XTL Biopharmaceuticals	-2.04%	-6.98%	-24.53%	+175.86%	+100.00%

The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)

Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …

Click here to see the presentation now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	1.2983 of 5 stars	3.5	0.0	0.0	0.0	3.0	0.8	0.6
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.00	Buy	$24.00	352.83% Upside
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ICOTF, CAPR, NVUS, TRPX, and XTLB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/25/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/1/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$25.18M	6.63	N/A	N/A	$0.73 per share	7.26
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	$13.13 per share	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	$0.41 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$22.29M	-$0.87	N/A	44.17	N/A	-88.52%	-299.67%	-45.54%	5/13/2024 (Confirmed)
ICOTF iCo Therapeutics	-$1.11M	-$0.40	N/A	∞	N/A	N/A	N/A	-288.85%	N/A
NVUS Novus Therapeutics	-$16.01M	-$21.58	N/A	N/A	N/A	N/A	-133.49%	-30.52%	N/A
TRPX Therapix Biosciences	-$4.79M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	-$1.78M	-$0.42	N/A	∞	N/A	N/A	-73.05%	-68.83%	5/21/2024 (Estimated)

Latest ICOTF, CAPR, NVUS, TRPX, and XTLB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2024	N/A	CAPR Capricor Therapeutics	-$0.11	N/A	+$0.11	N/A	N/A	N/A
2/29/2024	Q4 2023	CAPR Capricor Therapeutics	-$0.23	-$0.02	+$0.21	-$0.02	$5.80 million	$12.09 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	1.63	1.63
ICOTF iCo Therapeutics	N/A	0.72	0.72
NVUS Novus Therapeutics	N/A	18.78	18.78
TRPX Therapix Biosciences	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	9.93	9.93

Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
ICOTF iCo Therapeutics	N/A
NVUS Novus Therapeutics	N/A
TRPX Therapix Biosciences	14.32%
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	12.00%
ICOTF iCo Therapeutics	N/A
NVUS Novus Therapeutics	2.20%
TRPX Therapix Biosciences	N/A
XTLB XTL Biopharmaceuticals	29.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	N/A	31.50 million	27.72 million	Optionable
ICOTF iCo Therapeutics	N/A	9.05 million	N/A	Not Optionable
NVUS Novus Therapeutics	7	1.44 million	N/A	Not Optionable
TRPX Therapix Biosciences	9	3.51 million	N/A	Not Optionable
XTLB XTL Biopharmaceuticals	N/A	5.45 million	3.87 million	Not Optionable

ICOTF, CAPR, NVUS, TRPX, and XTLB Headlines

Source	Headline
	XTL Biopharmaceuticals Ltd. ADR wsj.com - April 26 at 6:16 AM
	U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03% msn.com - March 20 at 8:50 PM
	US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views msn.com - March 20 at 3:48 PM
	Dow Surges 350 Points; Fed Holds Rates Steady markets.businessinsider.com - March 20 at 3:48 PM
	Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher markets.businessinsider.com - March 20 at 3:48 PM
	XTL To Aquire The Social Proxy globenewswire.com - March 20 at 10:15 AM
	XTL Biopharmaceuticals Ltd ADR (XTLB) investing.com - February 17 at 10:28 AM
	Call for Proposals raps.org - February 11 at 2:00 PM
	XTL Biopharmaceuticals Ltd (H2K2.MU) finance.yahoo.com - October 23 at 11:13 PM
	XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency finanznachrichten.de - October 23 at 12:16 AM
	XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel finanznachrichten.de - October 21 at 8:22 AM
	XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel finance.yahoo.com - October 20 at 7:35 PM
	XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency finance.yahoo.com - October 20 at 7:35 PM
	Is X T L Biopharmaceuticals Ltd (ADR) (XTLB) Stock a Good Investment? aaii.com - March 30 at 3:19 PM
	XTLB XTL Biopharmaceuticals Ltd. seekingalpha.com - October 1 at 8:47 PM
	X T L Biopharmaceuticals Ltd reuters.com - August 8 at 10:32 PM
	LIFE, TBLT and XTLB among pre market gainers seekingalpha.com - July 23 at 7:53 AM
	XTL Biopharmaceuticals Year to Date Total Returns (Daily) ycharts.com - December 18 at 11:24 PM
	XTL Biopharmaceuticals Dividend Per Share (TTM) ycharts.com - December 18 at 1:03 AM
	XTL Biopharmaceuticals Ltd. (XTLB) uk.finance.yahoo.com - December 15 at 10:18 AM
	X.T.L. Biopharmaceuticals Ltd. - ADR money.usnews.com - September 26 at 12:03 AM
	XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Up 1.8% This Year: What Should You Expect Next? stocksregister.com - August 23 at 4:44 PM
	Is XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Expensive At $4.67? Here’s How To Know. marketingsentinel.com - August 20 at 5:09 PM
	How Is XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Expected To Fare In The Coming Months? marketingsentinel.com - July 26 at 9:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Capricor Therapeutics

NASDAQ:CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

iCo Therapeutics

OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Novus Therapeutics

NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Therapix Biosciences

NASDAQ:TRPX

XTL Biopharmaceuticals

NASDAQ:XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial